Neurodegeneration Initiative

4.1 THE CHARITY'S OBJECTS (OBJECTS) ARE FOR THE PUBLIC BENEFIT (A) TO PRESERVE AND ADVANCE HUMAN HEALTH AND (B) TO RELIEVE THOSE IN NEED BY REASON OF ILL-HEALTH, IN EACH CASE INCLUDING WITHOUT LIMITATION THE CAUSE, PROGRESSION, TREATMENT, DELAY AND/OR CURE OF NEURODEGENERATIVE CONDITIONS AND IN PARTICULAR BUT NOT EXCLUSIVELY BY SUPPORTING:4.1.1 THE ADVANCEMENT AND ADOPTION OF INNOVATIVE TREATMENTS THROUGH CLINICAL TRIAL RECRUITMENT, INFRASTRUCTURE, TECHNOLOGY (INCLUDING BUT NOT LIMITED TO AI), AND OTHER MEANS; 4.1.2 RESEARCH INTO NEURODEGENERATIVE CONDITIONS AND THE DISSEMINATION OF THE USEFUL RESULTS THEREOF WHETHER THROUGH PUBLICATION, PUBLIC ENGAGEMENT, CONFERENCES, WORKSHOPS, OPEN ACCESS REPOSITORIES, LICENSING, SPIN OUT COMPANIES, AND/OR OTHER FORMS OF COLLABORATION AND DISSEMINATION;4.1.3 THE CREATION, DEVELOPMENT, VALIDATION AND RESPONSIBLE ADOPTION OF NEW AND EMERGING TECHNOLOGIES AND APPROACHES FOR BIOMARKERS FOR THE DETECTION, STRATIFICATION, AND TREATMENT OF NEURODEGENERATIVE CONDITIONS;4.1.4 THE CREATION AND USE OF DATA, DIGITAL ASSETS AND OTHER TECHNOLOGIES;4.1.5 THE ALIGNMENT OF TRANSLATIONAL RESEARCH, CLINICAL PRACTICE, NETWORKS, AND REGULATORY FRAMEWORKS; 4.1.6 COLLABORATION WITH AND BETWEEN CHARITIES, EXPERTS, PATIENTS, THE NHS, GOVERNMENT, PUBLIC BODIES, INDUSTRY, REGULATORS, PEOPLE'S FORUMS, AND OTHER STAKEHOLDERS; 4.1.7 IMPROVED ACCESS TO PATIENT AND POPULATION LEVEL DATA SOURCES (INCLUDING CLINICAL, RESEARCH, GENOMIC, IMAGING, BIOMARKERS, AND REAL-WORLD DATA) THROUGH THE PROVISION OF FEDERATED DATA PLATFORMS AND INFRASTRUCTURE TO ENABLE THE SECURE DISCOVERY, LINKAGE, ANALYSIS AND USE OF HEALTH AND SOCIAL CARE INFORMATION AND EVIDENCE RELATING TO PEOPLE AT RISK OF OR LIVING WITH DEMENTIA AND OTHER NEURODEGENERATIVE CONDITIONS; AND4.1.8 THOSE WHO PROVIDE CARE (WHETHER AS INDIVIDUALS, ORGANISATIONS OR NETWORKS, AND WHETHER SUCH CARE IS PROFESSIONAL, FAMILIAL, VOLUNTARY OR INFORMAL) TO PEOPLE LIVING WITH NEURODEGENERATIVE CONDITIONS THROUGH THE PROVISION OF INFORMATION, RESOURCES, TRAINING AND OTHER FORMS OF SUPPORT.4.2 FOR THE PURPOSES OF THIS ARTICLE 4 AND AS USED ELSEWHERE IN THESE ARTICLES:4.2.1 "AI" MEANS ARTIFICIAL INTELLIGENCE, BEING COMPUTER SYSTEMS, ALGORITHMS, SOFTWARE, OR TECHNOLOGIES THAT PROCESS AND ANALYSE DATA TO PERFORM TASKS, MAKE PREDICTIONS, GENERATE CONTENT, OR SUPPORT DECISION-MAKING WITH VARYING DEGREES OF AUTONOMY. THIS INCLUDES BUT IS NOT LIMITED TO MACHINE LEARNING, GENERATIVE ARTIFICIAL INTELLIGENCE, NATURAL LANGUAGE PROCESSING, COMPUTER VISION, AND OTHER COMPUTATIONAL METHODS THAT ADAPT OR IMPROVE THROUGH EXPERIENCE;4.2.2 "BIOMARKERS" MEANS MEASURABLE INDICATORS OF BIOLOGICAL, PATHOLOGICAL, OR FUNCTIONAL STATES, INCLUDING MOLECULAR, GENETIC, IMAGING, PHYSIOLOGICAL, BEHAVIOURAL, AND DIGITAL MEASURES, USED TO DETECT OR MONITOR DISEASE, ASSESS RISK OR PROGRESSION, SUPPORT DIAGNOSIS OR PROGNOSIS, AND EVALUATE RESPONSES TO TREATMENT;4.2.3 "NEURODEGENERATIVE CONDITIONS" MEANS CONDITIONS, DISORDERS OR DISEASES CHARACTERISED BY PROGRESSIVE NEURONAL CELL DEATH ACCOMPANIED BY COGNITIVE AND MOTOR DYSFUNCTIONS, WHICH IS ASSOCIATED WITH CHRONIC PROGRESSIVE DISEASES INCLUDING BUT NOT LIMITED TO ALZHEIMER'S DISEASE, DEMENTIA, PARKINSON'S DISEASE, HUNTINGTON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, AND OTHER DISEASES OR CONDITIONS HAVING A SIMILAR OR RELATED CAUSE; 4.2.4 "NHS" MEANS THE UK'S PUBLICLY FUNDED NATIONAL HEALTHCARE SYSTEM AND ITS CONSTITUENT BODIES ACROSS THE UK INCLUDING NHS ENGLAND, NHS WALES, HEALTH AND SOCIAL CARE NORTHERN IRELAND, AND NHS SCOTLAND; AND 4.2.5 "REGULATORS" INCLUDES BUT IS NOT LIMITED TO, THE MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AUTHORITY, THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE, AND THE SCOTTISH MEDICINES CONSORTIUM.